Adagrasib Shows “Durable Clinical Benefit” in Advanced KRAS-Mutant NSCLC
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.
Researchers investigated the effects of multidisciplinary clinical management of IMDC in patients with NSCLC undergoing treatment with immune checkpoint inhibitors.
Researchers have found evidence to suggest that patients with metastatic non-small cell lung cancer have unique gut microbiomes.
Neoadjuvant camrelizumab in combination with either platinum-doublet chemotherapy or apatinib has demonstrated efficacy in stage II-III NSCLC, according to researchers.
Divarasib produced responses in patients with non-small cell lung cancer, colorectal cancer, and other solid tumors in a phase 1 trial.
Adding tumor-treating fields therapy to standard treatment improves survival in patients with metastatic non-small cell lung cancer, a study suggests.
Researchers investigated the association between preexisting interstitial lung abnormalities and immune checkpoint inhibitor-related pneumonitis.
Researchers investigated the intercorrelation between sleep disturbance, fatigue, anxiety, and depression and cortisol rhythm in patients with advanced lung cancer.